Beam Therapeutics (BEAM) Net Equity Issued and Repurchased (2021 - 2023)

Beam Therapeutics (BEAM) has reported Net Equity Issued and Repurchased for 3 consecutive years, with $34.9 million the latest figure, recorded in Q3 2023.

• In Q3 2023, Net Equity Issued and Repurchased changed N/A year-over-year to $34.9 million; the TTM figure through Dec 2023 stood at $236.6 million (up 118.52% YoY), while the FY2023 annual figure was $236.6 million, up 118.52% from the prior year.
• Net Equity Issued and Repurchased slipped to $34.9 million in Q3 2023 per BEAM's latest filing, from $107.6 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $318.9 million in Q3 2021 and bottomed at $20.2 million in Q4 2021.
• Historically, Net Equity Issued and Repurchased has averaged $110.2 million across 3 years, with a median of $74.0 million in 2022.
• Annual changes were most pronounced in 2022 — Net Equity Issued and Repurchased tumbled 85.87% — and 2023, when it jumped 381.36%.
• Beam Therapeutics' Net Equity Issued and Repurchased stood at $20.2 million in 2021, then jumped by 57.54% to $31.9 million in 2022, then grew by 9.57% to $34.9 million in 2023.
• Business Quant data shows BEAM's Net Equity Issued and Repurchased at $34.9 million in Q3 2023, $107.6 million in Q2 2023, and $94.0 million in Q1 2023.